Diclofenac sodium

ArticlesMedicine Compliance Aid StabilityLactation Safety Information ·
419143009

Articles

Medicine Compliance Aid Stability

Voltarol RetardNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Voltarol Retard
Tablets 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture
12 August 2015

Diclomax RetardGalen Ltd

Galen Ltd
Diclomax Retard
Capsules 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light and moisture.
12 August 2015

genericDexcel Pharma Ltd

Dexcel Pharma Ltd
generic
Tablets 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture
12 August 2015

Voltarol 75mg SRNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Voltarol 75mg SR
Tablets 75mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture
12 August 2015

VoltarolNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Voltarol
Tablets dispersible 50mg
R1 · Red 1Stability data indicates that the drug is not suitable for CAs.
Unsuitable
Dispersible tablet
12 August 2015

VoltarolNovartis Pharmaceuticals UK Ltd

Novartis Pharmaceuticals UK Ltd
Voltarol
Tablets 25mg, 50mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture
12 August 2015

genericTeva UK Ltd

Teva UK Ltd
generic
Tablets 25mg, 50mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from light
12 August 2015

genericSandoz Ltd

Sandoz Ltd
generic
Tablets 75mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture
12 August 2015

MotifeneDaiichi Sankyo UK Ltd

Daiichi Sankyo UK Ltd
Motifene
Capsules 75mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture.
12 August 2015

Diclomax SRGalen Ltd

Galen Ltd
Diclomax SR
Capsules 75mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light. Protect from moisture.
12 August 2015

RhumalganSandoz Ltd

Sandoz Ltd
Rhumalgan
Capsules 100mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light and moisture.
14 September 2015

RhumalganSandoz Ltd

Sandoz Ltd
Rhumalgan
Capsules 75mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Protect from light and moisture.
14 September 2015

Lactation Safety Information

For oral/ rectal/ parenteral use

For oral/ rectal/ parenteral use
Extensive experience of safe use in breastfeeding
Limited published evidence of safety
No adverse effects reported in breastfed infants
Small amounts in breast milk
29 July 2020

Topical

Topical
Negligible milk levels anticipated as systemic absorption from topical formulations is low
Follow normal precautions for topical medicines (see summary)
29 July 2020

For ophthalmic use

For ophthalmic use
29 July 2020

For actinic keratitis

For actinic keratitis
Negligible milk levels anticipated as systemic absorption from topical formulations is low
Avoid contact of the breastfeeding infant with treated areas
30 October 2020